摘要
目的:比较西妥昔单抗与贝伐单抗分别联合FOLFOX4方案治疗晚期结直肠癌的临床疗效及安全性。方法:回顾性分析2008年9月至2012年9月经组织病理学证实的晚期结直肠癌患者49例,西妥昔单抗联合FOLFOX4方案组26例,贝伐单抗联合FOLFOX4方案组23例。两组患者在性别、年龄、病理类型、分期等方面大致平衡。观察各组临床疗效和治疗期间毒副反应。结果:贝伐单抗联合FOLFOX4方案治疗转移性结直肠癌有效率低于西妥昔单抗联合FOLFOX4方案(P<0.01)。两组间毒副反应发生率差异无统计学意义(P>0.05)。结论:西妥昔单抗联合化疗对K-Ras基因为野生型的转移性结直肠癌患者的疗效优于贝伐单抗,且耐受性好。
Objective： To compare the efficacy and safety of cetuximab and bevacizumab combined with FOLFOX4 regimen in treatment of patients with advanced colorectal cancer. Methods： From September 2008 to September 2012 retrospective analysis was performed on 49 cases with advanced colorectal cancer. Among the 49 patients,26 cases re-ceived cetuximab combined with FOLFOX4 regimen and 23 cases received and bevacizumab combined with FOLFOX4 regimen therapy. There were all balanced between the two groups in terms of sex, age, pathology and staging in patient characteristics. The efficacy and toxicity of the two groups were observed. Results： In the advanced colorectal patients, the efficieng of bevacizumab with FOLFOX4 treatment of metastatic colorectal cancer was lower than cetuximab com-bined with FOLFOX4（P 〈0.01）. There was no significant difference on adverse between the two groups（P 〉0.05）. Conclusion： Cetuximab combined with FOLFOX4 regimen for patients with advanced colorectal cancer was effective, and the tolerance was better.
出处
《现代肿瘤医学》
CAS
2017年第17期2781-2784,共4页
Journal of Modern Oncology
